Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 05 2018 - 4:05PM
Business Wire
Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the
Company), focused on developing and commercializing medicines to
improve the survival and quality of life of cancer patients, today
announced the grant of options to purchase 83,978 shares of its
common stock to four employees. The awards were granted as an
inducement material to the employees' acceptance of employment with
Verastem Oncology in accordance with Nasdaq Listing Rule
5635(c)(4). The options have an exercise price equal
to $5.21 per share, the closing price of Verastem
Oncology's common stock as reported by Nasdaq on December 3,
2018 and vest at a rate of 20% on the one-year anniversary of his
or her date of hire, and thereafter, at a rate of 5% of the shares
subject to the options at the end of each successive three-month
period, provided that the employee continues to serve as an
employee of or other service provider to Verastem Oncology on each
such vesting date.
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) is a commercial
biopharmaceutical company committed to the development and
commercialization of medicines to improve the lives of patients
diagnosed with cancer. We are driven by the strength, tenacity and
courage of those battling cancer – single-minded in our resolve to
deliver new therapies that not only keep cancer at bay, but improve
the lives of patients diagnosed with cancer. Because for us, it’s
personal.
Our first FDA approved product is now available for
the treatment of patients with certain types of indolent
non-Hodgkin’s lymphoma (iNHL). Our pipeline comprises product
candidates that seek to treat cancer by modulating the local tumor
microenvironment. For more information, please
visit www.verastem.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181205005650/en/
Verastem Oncology:Brian SullivanSenior Director, Corporate
Development+1 781-469-1636bsullivan@verastem.com
Media:Jeff
StoeckerFleishmanHillard+1-617-692-0509media@verastem.com
Investors:Joseph RayneArgot Partners+1
617-340-6075joseph@argotpartners.com
Verastem (NASDAQ:VSTM)
Historical Stock Chart
From Apr 2024 to May 2024
Verastem (NASDAQ:VSTM)
Historical Stock Chart
From May 2023 to May 2024